By Metro US
Posted on
TOKYO (Reuters) – Astrazeneca said on Friday it is beginning Phase 1/2 clinical trials in Japan of its coronavirus vaccine candidate.
Trials of the vaccine, known as AZD1222, will be conducted at multiple facilities in Japan, targeting 250 subjects, the company said in a release.
The British company is working with Daiichi Sankyo, JCR Pharma and other partners in Japan to make and distribute the vaccine.
(Reporting by Rocky Swift and Chris Gallagher in Tokyo; Editing by Tom Hogue)
Series Preview: Phillies Splash down in the 305 to Face Marlins
Stanford names basketball court “Tara VanDerveer Court” for retired Hall of Famer, winningest coach
Miro Heiskanen scores 2 power-play goals and Stars beat Avs 5-3 in Game 2 to even series
Doncic scores 29 points as Mavericks top Thunder 119-110 to tie series at 1-1
Artemi Panarin scores in overtime, Rangers beat Hurricanes 3-2 to take 3-0 series lead
Storms slam parts of Florida, Mississippi and elsewhere as cleanup from earlier tornadoes continues
Inside a makeshift shelter saving hundreds of dogs from floods in southern Brazil
Ukraine says Russia is trying to break through its defenses in the northeastern Kharkiv region
A bus plunges off a bridge in the Russian city of St. Petersburg, killing 3 and injuring 6 others
Environmentalists attack a case holding a copy of the Magna Carta in London but document unscathed
Virginia judge to decide whether state law considers embryos as property
No sign of widespread lead exposure from Maui wildfires, Hawaii health officials say
States with abortion bans saw greater drops in medical school graduates applying for residencies
Here’s what to know if you are traveling abroad with your dog
